A double blind, placebo controlled study of a platelet activating factor antagonist in patients with rheumatoid arthritis.

Abstract

OBJECTIVE:

To evaluate the efficacy and tolerance of a platelet activating factor-acether (PAF) antagonist, BN 50730, in patients with rheumatoid arthritis (RA).

METHODS:

A total of 56 patients with active RA were enrolled in a multicenter, double blind, placebo controlled study of BN 50730. Patients received either BN 50730 (40 mg orally bid) or placebo for 84 days.

RESULTS:

Treatment with BN 50730 resulted in no improvement and was no more effective than placebo in improving clinical and biological indices of RA activity. Adverse events were observed in the 2 treatment groups, and BN 50730 was generally well tolerated.

CONCLUSION:

PAF antagonist BN 50730 at a daily dose of 80 mg was ineffective in the treatment of RA.

• Authors: P Hilliquin, V Chermat-Izard, C J Menkes
• Journal: The Journal of rheumatology (J Rheumatol) Vol. 25 Issue 8 Pg. 1502-7 (Aug 1998) ISSN: 0315-162X [Print] Canada
• PMID: 9712091 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Antirheumatic Agents
• Azepines
• Platelet Activating Factor
• Platelet Aggregation Inhibitors
• Thienopyridines
• Triazoles
• BN 50730

Topics

• Adult
• Aged
• Antirheumatic Agents (adverse effects, therapeutic use)
• Arthritis, Rheumatoid (drug therapy)
• Azepines (adverse effects, therapeutic use)
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged
• Outcome Assessment, Health Care
• Platelet Activating Factor (antagonists & inhibitors)
• Platelet Aggregation Inhibitors (adverse effects, therapeutic use)
• Thienopyridines
• Treatment Outcome
• Triazoles (adverse effects, therapeutic use)